S. Bernasconi et al., FINAL HEIGHT IN NONGROWTH HORMONE-DEFICIENT CHILDREN TREATED WITH GROWTH-HORMONE, Clinical endocrinology, 47(3), 1997, pp. 261-266
OBJECTIVE To evaluate the final height of nongrowth hormone deficient
(N-GHD) children treated with growth hormone (GH). DESIGN Multicentre
retrospective study. PATIENTS 71 (54M/17F) N-GHD children (peak GH aft
er pharmacological stimulation >14-24 mU/l) who had been treated for 4
.19 +/- 0.14 years with GH (0.69 +/- 0.02 IU/kg/week). MEASUREMENTS He
ight(H) and height velocity (HV) expressed as standard deviation score
(SDS) for chronological age (CA) and bone age (BA), BA/CA ratio, and
predicted adult height (PAHSDS) were evaluated before and during treat
ment, and at each pubertal stage, Target height (TH), and final height
(FH) were also calculated, and expressed as SDS. RESULTS In the whole
group, HSDS for CA increased significantly after the first year on GH
, and remained significantly increased for 4 years. This did not occur
to HSDS for BA, owing to a significant increase in BAI CA after the f
irst year of therapy, In addition, this increase coincided with stages
4 and 5 of puberty, HVSDS for CA and BA also increased significantly
after the first year of treatment, and remained significantly elevated
for 4 years. PAHSDS did not change significantly during treatment, FH
SDS (-1.69 +/- 0.07) was similar to PAHSDS (-1.6 +/- 0.12) and target
height (THSDS) (-1.46 +/- 0.08), FHSDS was greater than or equal to TH
SDS in 36.6% of the patients, and greater than or equal to initial PAH
SDS in 34.5%. Male patients were subdivided into 2 groups (A and B), P
atients in Group A (n = 26) started treatment at puberty, while group
B (n = 28) consisted of subjects who started therapy during prepuberta
l years. Height, height velocity and predicted adult height showed the
same pattern as in the whole group, in each subgroup, BA/CA advanced
significantly in group A after the second year on GH and in group B, a
fter at least 3 years of therapy, FHSDS, THSDS, and PAHSDS were simila
r in both groups (-1.7 +/- 0.13, -1.29 +/- 0.2 and -1.39 +/- 0.15 in g
roup A and -1.48 +/- 0.11, -1.85 +/- 0.15 and -1.36 +/- 0.12 in group
B, respectively). However, in group B (prepubertal), FHSDS was greater
than or equal to initial PAHSDS in 60% of the patients and greater th
an or equal to THSDS in 40.7%, while in group A (pubertal), FHSDS was
greater than or equal to initial PAHSDS only in 22.7% of the patients
and greater than or equal to THSDS in 34.6%, FHSDS was found to be cor
related with THSDS, PAHSDS at the onset of treatment, and after 1 year
of treatment, The age at the beginning of puberty, and the duration o
f puberty were appropriate in all groups. CONCLUSIONS GH treatment was
effective in increasing height velocity of short non-GH-deficient chi
ldren, but final height was not definitely improved with respect to in
itial predicted adult height.